Navigation Links
Newly Approved HIV Drug Shows Great Promise
Date:1/30/2008

Pricing Level Should Improve Access

WASHINGTON, Jan. 30 /PRNewswire/ -- The AIDS Institute, a national public policy research, advocacy, and education organization, is encouraged with the FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade. TMC125/etravirine was developed by Tibotec Pharmaceuticals, Ltd. and will be marketed in the U.S. by Tibotec Therapeutics as Intelence(R), a division of Ortho Biotech Products, L.P. The company announced introductory pricing for the new NNRTI at $21.80 per day, which is substantially lower than other recently introduced antiretrovirals.

In a Title II Community AIDS National Network release dated January 19, 2008, Dr. Donna Christian-Chistensen, Chair of the Congressional Black Caucus Health Brain Trust stated: "The efficacy that Intelence (TMC125/etravirine) has shown in the DUET studies is impressive. Intelence is an important new HIV medication that, for the first time, re-opens the NNRTI class to patients with NNRTI-resistant virus. We applaud Tibotec for its efforts to make this innovative new medication available and accessible to people living with HIV."

The U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti-HIV medication. This is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced adult patients with HIV resistant to an NNRTI and other antiretroviral (ARV) agents. Intelence, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment- experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other ARV agents. This indication is based on Week 24 analyses from two randomized, double-blind, placebo-controlled trials of Intelence. Both studies were conducted in clinically advanced
'/>"/>

SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
7. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
8. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
9. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... , May 30, 2015  Eisai Inc. announced today the ... that eribulin met the study,s primary endpoint evaluating overall survival ... (ADI), two types of advanced soft tissue sarcoma. These data ... of the American Society of Clinical Oncology (ASCO) in ... conference on Saturday, May 30, and also in an oral ...
(Date:5/29/2015)... 29, 2015  Excite Medical was established by its ... years, Excite Medical, under the leadership of Mr. ... with a solid track record of providing unparalleled service ... distributor base.  Photo - http://photos.prnewswire.com/prnh/20150529/219412 ... has been possible, in large part, due to ...
(Date:5/29/2015)... BRUNSWICK, N.J. , May 29, 2015 ... start-up companies originally funded with investments from Foundation Venture ... research at Bio International 2015 as part of the ... Conference, announced FVCG President James M. Golubieski . ... for the biotechnology industry, will be held in ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3
... Oct. 11 Essentialis, Inc. announced today that the ... has issued U.S. Patent No. 7,799,777 entitled Salts ... The patent claims a novel composition of a polymorph ... lead product, DCCR.  Essentialis has successfully completed phase 2b ...
... 11 Pioneer Surgical Technology, Inc., a leader ... plan to establish a manufacturing and distribution facility ... IDA (Ireland Development Authority) to evaluate potential sites ... facility will support Pioneer,s continued growth in Europe ...
Cached Medicine Technology:Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio 2Pioneer® Surgical Technology, Inc. Announces Plans to Establish Manufacturing and Distribution Facility in Ireland 2
(Date:5/30/2015)... 2015 Thousands of aesthetic industry professionals ... sponsored by the American Society for Aesthetic Plastic Surgery ... was Zeltiq, the parent company of one of the ... With blazing growth, the one-of-a-kind device just sold its ... is currently in the news for gaining the FDA’s ...
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... At 73 years old, Lynn Kendall is happily ... attributes to a lifetime of being health-conscious. She passes on ... of her new book titled “ Cook for Health and ... and Longevity” features a collection of recipes and ideas for ... It is designed to encourage a lifestyle of correct eating ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 Key ... California, is proud to announce their June 2015 featured ... apartment community in San Francisco, Key Housing is helping ... housing in what is one of the tightest apartment ... a plum posting, and understandably anyone who requires temporary ...
(Date:5/30/2015)... 30, 2015 Venus Viva has proven ... large pores, deep wrinkles, stretch marks, pigmentation irregularities, and ... such as Dr. F. Victor Rueckl of Lakes Dermatology ... trials in Las Vegas. This body image solution combines ... system that delivers proven results through a skin heating ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3
... , BATESVILLE, Ind. , Feb. ... Net revenue decreased 3% year-over-year, due primarily to a lower number of ... net income increased more than 11% during the same period. ... year. Cash flow from operations increased 56.2% to ...
... ... ... Sunquest , a leading provider of healthcare diagnostic information technology and outreach solutions, continues ... take on the additional role of Director of Innovation, the first of two reorganizational ...
... ... Authentically green and actively healthy skincare for babies a ... from "The Very Hungry Caterpillar." The first company to deliver clinically ... the skin, Episencial formulas are made exclusively from all natural ingredients ...
... ... growth of 30% to 31st December 2009. By comparison, growth in the human capital management ... ... Lyle Potgieter CEO of PeopleStreme cited several factors for the growth primarily the appetite for ...
... ... ... for women to get ready for Valentine,s Day ? Why not throw a party ... will be tailgating for Valentine’s Day., , ,Valentine’s Day isn’t just for couples anymore as ...
... ... staff of Vitabot is doing their part to ensure a healthier tomorrow. , , ... (PRWEB) February 4, 2010 -- In the midst of ... to keep afloat. Don,t tell that to the staff at Vitabot. By embracing a ...
Cached Medicine News:Health News:Hillenbrand Reports Results for First Quarter 2010 2Health News:Hillenbrand Reports Results for First Quarter 2010 3Health News:Hillenbrand Reports Results for First Quarter 2010 4Health News:Hillenbrand Reports Results for First Quarter 2010 5Health News:Hillenbrand Reports Results for First Quarter 2010 6Health News:Hillenbrand Reports Results for First Quarter 2010 7Health News:Hillenbrand Reports Results for First Quarter 2010 8Health News:Hillenbrand Reports Results for First Quarter 2010 9Health News:Hillenbrand Reports Results for First Quarter 2010 10Health News:Sunquest Advances Investment in Innovations Team 2Health News:Episencial All Natural Skincare for Babies, Kids and Planet Now on Shelves at Target 2Health News:Episencial All Natural Skincare for Babies, Kids and Planet Now on Shelves at Target 3Health News:Episencial All Natural Skincare for Babies, Kids and Planet Now on Shelves at Target 4Health News:Episencial All Natural Skincare for Babies, Kids and Planet Now on Shelves at Target 5Health News:PeopleStreme Revenue up 30% Year on Year 2Health News:Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research 2Health News:Vitabot Online Nutrition Redefines Corporate Wellness 2Health News:Vitabot Online Nutrition Redefines Corporate Wellness 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: